

MD Anderson Ovarian SPORE publications – 2014

1. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Stadler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB. **A pan-cancer proteomic perspective on The Cancer Genome Atlas**. Nat Commun 5:3887, 2014. PMID: 24871328; PMCID: PMC4109726.
2. Bakkar R, Gershenson D, Fox P, Vu K, Zenali M, Silva E. **Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses**. Int J Gynecol Pathol 33(3):302-8, 2014. PMID: 24681743.
3. Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN Jr, Eblen ST. **EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer**. Carcinogenesis 35(5):1100-9, 2014. PMID: 24379240; PMCID: PMC4004201.
4. Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DM. **Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group**. Cancer 120(3):344-51, 2014. PMCID: PMC4250045.
5. Burton-Chase AM, Hovick SR, Sun CC, Boyd-Rogers S, Lynch PM, Lu KH, Peterson SK. **Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome**. Clin Genet 86(2):185-9, 2014. PMCID: PMC3909028.
6. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. **Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence**. Breast Cancer Res 16(6):3417, 2014. PMCID: PMC4326485.
7. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peugot S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. **Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers**. Cancer Cell 26(6):863-79, 2014. PMCID: PMC4261159.
8. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeny LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G, for AOCs/ACS group, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlov I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dörk T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despiere E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. **Risk of ovarian cancer and the NF- κ B pathway: genetic association with IL1A and TNFSF10**. Cancer Res 74(3):852-61, 2014. PMCID: PMC3946482.

9. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V. **Autocrine effects of tumor-derived complement**. *Cell Rep* 6(6):1085-95, 2014. PMID: 24613353; PMCID: PMC4084868.
10. Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. **Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904**. *Eur J Cancer* 50(9):1638-48, 2014. PMID: 24709487; PMCID: PMC4098779.
11. Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. **Monocyte subpopulations in angiogenesis**. *Cancer Res* 74(5):1287-93, 2014. PMID: 24556724; PMCID: PMC4040005.
12. Daniels MS, Babb SA, King RH, Urbauer DL, Batte BA, Brandt AC, Amos CI, Buchanan AH, Mutch DG, Lu KH. **Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPro: a multi-institution study**. *J Clin Oncol* 32(12):1249-55, 2014. PMID: 24638001.
13. Daniels MS, Lu KH. **Reply to D. Braun et al**. *J Clin Oncol* 32(32):3683, 2014. PMID: 25199758.
14. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. **Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance**. *J Clin Invest* 124(6):2611-25, 2014. PMCID: PMC4038562.
15. Davis AN, Afshar-Kharghan V, Sood AK. **Platelet effects on ovarian cancer**. *Semin Oncol* 41(3):378-84, 2014. PMID: 25023353; PMCID: PMC4100073.
16. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC Jr, Champlin RE, Cooper LJ. **Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies**. *Clin Cancer Res* 20(22):5708-19, 2014. PMID: 24833662; PMCID: PMC4233015.
17. Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, Li Y, Yang Q, Liu J, Wei JJ, Shao C, Liu Z, Kong B. **miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma**. *Oncotarget* 5(21):10816-29, 2014. PMCID: PMC4279412.
18. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G, Australian Cancer Study, Australian Ovarian Cancer Study Group, Lu Y, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Despiere E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Friel G, Moysich KB, Odunsi K, Sucheston-Campbell L, Lurie G, Goodman MT, Carney ME, Thompson PJ, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Nevanlinna H, Pelttari LM, Butzow R, Bunker CH, Modugno F, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Karlan BY, Walsh C, Lester J, Jensen A, Kjær SK, Høgdall CK, Høgdall E, Lundvall L, Sellers TA, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Giles GG, Baglietto L, Severi G, Southey MC, Liang D, Wu X, Lu K, Hildebrandt MA, Levine DA, Bisogna M, Schildkraut JM, Iversen ES, Weber RP, Berchuck A, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Chandran U, Orlov I, Olson SH, Wik E, Salvesen HB, Bjorge L, Halle MK, van Altena AM, Aben KK, Kiemenev LA, Massuger LF, Pejovic T, Bean YT, Cybulski C, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Dicks E, Dennis J, Easton DF, Song H, Tyrer JP, Pharoah PD, Eccles D, Campbell IG, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Flanagan JM, Paul J, Brown R, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Wu AH, Pearce CL, Pike MC, Dansonka-Mieszkowska A, Rzepecka IK, Szafron LM, Kupryjanczyk J, Cook LS, Le ND, Brooks-Wilson A, Ovarian Cancer Association Consortium. **Genome-wide association study of subtype-specific**

epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 133(5):481-97, 2014. PMID: PMC4063682.

19. Fader AN, Java J, Krivak TC, Bristow RE, Tergas AI, Bookman MA, Armstrong DK, Tanner EJ, Gershenson DM. **The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.** Gynecol Oncol 132(3):560-5, 2014. PMID: PMC4390028.
20. Gao M, Liang J, Lu Y, Guo H, German P, Bai S, Jonasch E, Yang X, Mills GB, Ding Z. **Site-specific activation of AKT protects cells from death induced by glucose deprivation.** Oncogene 33(6):745-55, 2014. PMID: 23396361; PMID: PMC3874430.
21. Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. **Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.** Mol Cancer Ther 13(7):1750-7, 2014. PMID: 24755199; PMID: PMC4090269.
22. Gizzatov A, Stigliano C, Ananta JS, Sethi R, Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi P. **Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer.** Cancer Lett 352(1):97-101, 2014. PMID: 24931336.
23. Gourley C, Farley J, Provencher DM, Pignata S, Mileshekin L, Harter P, Maenpaa J, Kim JW, Pujaide-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D. **Gynecologic Cancer InterGroup (GCIg) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.** Int J Gynecol Cancer 24(9 Suppl 3):S9-13, 2014. PMID: 25341587.
24. Graybill WS, Coleman RL. **Vintafolide: a novel targeted agent for epithelial ovarian cancer.** Future Oncol 10(4):541-8, 2014. PMID: 24754586.
25. Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, Zhang W. **MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.** Oncol Rep 31(5):2021-8, 2014. PMID: 24677166; PMID: PMC4020617.
26. Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang W. **Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions.** J Hematol Oncol 7:19, 2014. PMID: 24598126; PMID: PMC3973872.
27. Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu X. **The RNA-Binding Protein DDX1 Promotes Primary MicroRNA Maturation and Inhibits Ovarian Tumor Progression.** Cell Rep 8(5):1447-60, 2014. PMID: 25176654; PMID: PMC4163106.
28. Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A. **Gynecologic Cancer InterGroup (GCIg) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).** Int J Gynecol Cancer 24(9 Suppl 3):S5-8, 2014. PMID: 25341581.
29. Herzog TJ, Alvarez RD, Secord A, Goff BA, Mannel RS, Monk BJ, Coleman RL. **SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.** Gynecol Oncol 135(1):3-7, 2014. PMID: 25124162.
30. Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Vilella JA, Alvarez RD. **Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.** Gynecol Oncol 132(1):8-17, 2014. PMID: 24239753.

31. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. **Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.** *Gynecol Oncol* 133(2):283-6, 2014. PMID: PMC4035022.
32. Holman LL, Lu KH, Bast RC Jr, Hernandez MA, Bodurka DC, Skates S, Sun CC. **Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening.** *Am J Obstet Gynecol* 210(3):257.e1-6, 2014. PMID: 24246524; PMID: PMC4001707.
33. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. **Notch3 pathway alterations in ovarian cancer.** *Cancer Res* 74(12):3282-93, 2014. PMID: 24743243; PMID: PMC4058356.
34. Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L. **A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer.** *Cancer Cell* 26(3):344-57, 2014. PMID: 25203321; PMID: PMC4159613.
35. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanappapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. **Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.** *Clin Cancer Res* 20(7):1846-55, 2014. PMID: 24486585; PMID: PMC3975695.
36. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. **Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.** *Cell Rep* 6(2):377-87, 2014. PMID: PMC4409143.
37. Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, Mills GB, Sood A, Lee JS. **Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.** *Anticancer Res* 34(2):811-7, 2014. PMID: 24511017; PMID: PMC4082822.
38. Johnson R, Halder G. **The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.** *Nat Rev Drug Discov* 13(1):63-79, 2014. PMID: 24336504; PMID: PMC4167640.
39. Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy S, Zeng Y, Shah VH, Sood AK, Ramakrishnan S. **Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.** *Proc Natl Acad Sci U S A* 111(14):5331-6, 2014. PMID: PMC3986124.
40. Judd J, Ho ML, Tiwari A, Gomez EJ, Dempsey C, Van Vliet K, Igoshin OA, Silberg JJ, Agbandje-McKenna M, Suh J. **Tunable protease-activatable virus nanonodes.** *ACS Nano* 8(5):4740-6, 2014. PMID: 24796495; PMID: PMC4046807.
41. Kannan K, Coarfa C, Rajapakshe K, Hawkins SM, Matzuk MM, Milosavljevic A, Yen L. **CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.** *PLoS Genet* 10(3):e1004216, 2014. PMID: 24675677; PMID: PMC3967933.
42. Kelemen LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, Rossing MA, Wang Q, Dicks E, Tyrer JP, Song H, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Timorek A, Menon U, Gentry-Maharaj A, Gayther SA, Ramus SJ, Narod SA, Risch HA, McLaughlin JR, Siddiqui N, Glasspool R, Paul J, Carty K, Gronwald J, Lubiński J, Jakubowska A, Cybulski C, Kiemeny LA,

Massuger LF, van Altena AM, Aben KK, Olson SH, Orlow I, Cramer DW, Levine DA, Bisogna M, Giles GG, Southey MC, Bruinsma F, Kjaer SK, Høgdall E, Jensen A, Høgdall CK, Lundvall L, Engelholm SA, Heitz F, du Bois A, Harter P, Schwaab I, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Thompson PJ, Lurie G, Wilkens LR, Lambrechts D, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Beesley J, AOCs Study Group/ACS Investigators, Fasching PA, Beckmann MW, Hein A, Ekici AB, Doherty JA, Wu AH, Pearce CL, Pike MC, Stram D, Chang-Claude J, Rudolph A, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Bogdanova N, Antonenkova N, Odunsi K, Edwards RP, Kelley JL, Modugno F, Ness RB, Karlan BY, Walsh C, Lester J, Orsulic S, Fridley BL, Vierkant RA, Cunningham JM, Wu X, Lu K, Liang D, Hildebrandt MA, Weber RP, Iversen ES, Tworoger SS, Poole EM, Salvesen HB, Krakstad C, Bjorge L, Tangen IL, Pejovic T, Bean Y, Kellar M, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Campbell IG, Eccles D, Whittemore AS, Sieh W, Rothstein JH, Anton-Culver H, Ziogas A, Phelan CM, Moysich KB, Goode EL, Schildkraut JM, Berchuck A, Pharoah PD, Sellers TA, Brooks-Wilson A, Cook LS, Le ND. **Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.** *Mol Nutr Food Res* 58(10):2023-35, 2014. PMID: PMC4197821.

43. Kim TH, Yoo JY, Kim HI, Gilbert J, Ku BJ, Li J, Mills GB, Broaddus RR, Lydon JP, Lim JM, Yoon HG, Jeong JW. **Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation.** *Cancer Res* 74(24):7371-82, 2014. PMID: PMC4268053.
44. Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, Miller D, Moore D, Petereit D, Schefter T, Small W Jr, Yashar C, Viswanathan AN, American Society for Radiation Oncology. **The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline.** *Pract Radiat Oncol* 4(3):137-44, 2014. PMID: 24766678.
45. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. **Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.** *Nat Commun* 5:5092, 2014. PMID: PMC4185407.
46. Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J, Wei JJ, Zhang ZH, Liu J. **Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis.** *Int J Clin Exp Pathol* 7(3):848-57, 2014. PMID: PMC3971287.
47. Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, Xue F, Zhang W. **MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.** *J Pathol* 233(3):308-18, 2014. PMID: 24604117; PMID: PMC4144705.
48. Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast RC Jr. **DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells.** *Autophagy* 10(6):1071-92, 2014. PMID: 24879154; PMID: PMC4091169.
49. Lu Z, Yang H, Sutton MN, Yang M, Clarke CH, Liao WS, Bast RC Jr. **ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXO3a-mediated induction of Rab7.** *Cell Death Differ* 21(8):1275-89, 2014. PMID: PMC4085535.
50. Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB, Hennessey BT. **OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.** *Mol Cancer* 13:241, 2014. PMID: PMC4219121.
51. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. **Platelet-derived growth factor receptor alpha (PDGFR α) targeting and relevant biomarkers in ovarian carcinoma.** *Gynecol Oncol* 132(1):166-75, 2014.

PMID: 24183729; PMCID: PMC3946949.

52. Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK. **Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.** *Gynecol Oncol* 133(3):473-9, 2014. PMID: 24674832; PMCID: PMC4170217.
53. Matsuo K, Yoshino K, Hiramatsu K, Banzai C, Hasegawa K, Yasuda M, Nishimura M, Sheridan TB, Ikeda Y, Shiki Y, Mabuchi S, Enomoto T, Kimura T, Fujiwara K, Roman LD, Sood AK. **Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer.** *Obstet Gynecol* 123(5):957-65, 2014. PMID: 24785846; PMCID: PMC4174541.
54. Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y, Wagar EA, Wu X. **Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.** *Clin Chem* 60(1):222-32, 2014. PMCID: PMC4437198.
55. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. **Platelets and cancer: a casual or causal relationship: revisited.** *Cancer Metastasis Rev* 33(1):231-69, 2014. PMID: 24696047; PMCID: PMC4186918.
56. Mertins P, Yang F, Liu T, Mani DR, Petyuk VA, Gillette MA, Clauser KR, Qiao JW, Gritsenko MA, Moore RJ, Levine DA, Townsend R, Erdmann-Gilmore P, Snider JE, Davies SR, Ruggles KV, Fenyo D, Kitchens RT, Li S, Olvera N, Dao F, Rodriguez H, Chan DW, Liebler D, White F, Rodland KD, Mills GB, Smith RD, Paulovich AG, Ellis M, Carr SA. **Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.** *Mol Cell Proteomics* 13(7):1690-704, 2014. PMCID: PMC4083109.
57. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. **Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.** *Lancet Oncol* 15(8):799-808, 2014. PMID: 24950985.
58. Mullany LK, Liu Z, Wong KK, Deneke V, Ren YA, Herron A, Richards JS. **Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases.** *Mol Endocrinol* 28(1):127-37, 2014. PMID: 24264574; PMCID: PMC3874458.
59. Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. **Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.** *Oncogene* 33(22):2846-56, 2014. PMCID: PMC4115609.
60. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. **Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.** *Oncotarget* 5(7):1846-55, 2014. PMCID: PMC4039109.
61. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. **Hematogenous metastasis of ovarian cancer: rethinking mode of spread.** *Cancer Cell* 26(1):77-91, 2014. PMID: 25026212; PMCID: PMC4100212.
62. Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. **Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.** *Cancer Biol Ther*

15(8):1061-7, 2014. PMID: 24841852; PMCID: PMC4119073.

63. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK. **Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes.** *Fam Cancer* 13(2):291-9, 2014. PMCID: PMC4159051.
64. Rytelwski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick J. **BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.** *Mol Oncol* 8(8):1429-40, 2014. PMID: 24974076.
65. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. **Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.** *J Clin Oncol* 32(29):3275-83, 2014. PMCID: PMC4178524.
66. Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD. **Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010).** *Eur J Cancer* 50(11):1942-50, 2014. PMID: 24857045.
67. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanappapras D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, DeGeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. **Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.** *Cancer Biol Ther* 15(7):919-29, 2014. PMID: 24755674; PMCID: PMC4100993.
68. Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT. **Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.** *Gynecol Oncol* 133(1):100-4, 2014. PMCID: PMC4000233.
69. Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, Patel H, Sood A, Hu W, Patwa R, Blake P, Chirina P, Oh Jeong J, Lim H, Goy A, Pecora A, Suh KS. **Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.** *J Ovarian Res* 7:109, 2014. PMCID: PMC4271347.
70. Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL. **Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study.** *Br J Cancer* 111(5):843-50, 2014. PMCID: PMC4150278.
71. Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, Gilks B, Tinker AV, Clarke B, McAlpine JN, Huntsman D. **Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.** *BMC Cancer* 14:982, 2014. PMCID: PMC4320586.
72. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. **Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.** *Clin Cancer Res* 20(12):3280-8, 2014. PMID: 24756370; PMCID: PMC4062703.
73. Wan G, Liu Y, Han C, Zhang X, Lu X. **Noncoding RNAs in DNA repair and genome integrity.** *Antioxid Redox Signal* 20(4):655-77, 2014. PMID: 23879367; PMCID: PMC3901350.
74. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. **Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.** *Cell Rep*

7(2):488-500, 2014. PMID: 24703838; PMCID: PMC4038960.

75. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS. **A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.** *BMC Cancer* 14:120, 2014. PMCID: PMC3941949.
76. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. **RNAi therapies: drugging the undruggable.** *Sci Transl Med* 6(240):240ps7, 2014. PMID: 24920658; PMCID: PMC4154139.
77. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. **2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.** *Nat Commun* 5:3459, 2014. PMID: 24619206; PMCID: PMC4112501.
78. Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D. **Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.** *Mol Syst Biol* 10:728, 2014. PMID: 24799285; PMCID: PMC4188042.
79. Yeung TL, Leung CS, Mok SC. **CAF reprogramming inhibits ovarian cancer progression.** *Cell Cycle* 13(24):3783-4, 2014. PMID: 25483059.
80. Zhang S, Mercado-Uribe I, Liu J. **Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel.** *Int J Cancer* 134(3):508-18, 2014. PMID: 23754740; PMCID: PMC4175522.
81. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. **Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.** *Oncogene* 33(1):116-28, 2014. PMID: 23524583; PMCID: PMC3844126.